BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)

LibiGel, BPAX's product, received a positive safety rating, expect company to make profits. I'm buying!

time to throw in the towel

Should be above 1$

i got in at .67 and am happy I did. I am hoping for good news on feb. 14th. Trying to decide if I should sell before then?!

Oversold, a lot of short positions that need to exit(18.08m), and Bio-T-Gel FDA review date on February 14th, 2012. And GVAX is showing great potencial.

OMG, BPAX has run up 40% since i initiated my red thumb, and it has run on complete fluff. This company is in the tank ever since the recent CRL, and if they try to climb out, I believe shareholders will be substantially diluted. Short-term, I'm obviously effed and I expect more Seeking Alpha BS articles in the near future. Long-term this stock is coming down. Way down.

Way oversold on panic sell in December. Unintended results showing positive effectivenees ( 75% ) on preventing cardiovascular accidents in women. 90% chance of FDA approval Feb 14th ( possibly sooner ). Huge pipeline inc cancer drugs in late phase. Will shoot up to $5 or $6 ( could hit $10. )

it looks like a pump and dump on yahoo boards

T-gel should receive approval and any update on libigel will send this soaring

Selling for less than cash!

Should rally as we approach Feb 14, High Risk High Reward FDA approval play

bio-t gel approval

I'm still searching for that elusive CAPS multibagger, a quest which often causes me to hold my winners against my better judgement thereby losing everything I gained and more. Such was the case with BioSante, where I got in early and held my ground through a disastrous phase III data release. I expected the real battle of BioSante to come at the regulatory and commercialization level rather than the efficacy level, but so go my fortunes with binary catalysts.

I ditched an ugly losing score to refocus on the upcoming PDUFA for Bio-T-gel, postponed three months to February 14. It's hard to project much commercial success for yet another rub-on testosterone in a crowded market, but the drug is already partnered with Teva and stands a good chance of FDA approval. If it hadn't been for the Libigel smackdown, BioSante would probably be trading at a market cap over 100M just on the potential of Bio-T-gel. Hopefully I'll get the three bagger with BioSante that I missed the last time.

Takeover target

run before fda review nov.14,2011

Got in at $2.45 a couple of days ago. Three co. presentations this month and safety results of Libigel in Q4 plus a PDUFA date of 11/14 for Bio T Gel are going to make this company an attractive candidate for a potential run-up.

Follow me on twitter @JPZaragoza1

Cell Genesys shareholders got screwed by management. With GVAX back on track BioSante should do well.

Safety study closed, efficacy guaranteed, 4 million off label T scripts, in talks with "many many" potential buyers, 500 million very very conservative price. risk reward here is great.

I believe Libigel will get approved. Its already a 90% garuntee the FDA will approve it, and if they do it will be a sure monopoly since its the only product of its kind out. Not saying it will turn the company into the next Google, but it will definitely benefit the company